Ocugen Inc
OCGN1.410USD
-0.030-2.08%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
440.37MMarket Cap
LossP/E TTM
More Details of Ocugen Inc Company
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Leber congenital amaurosis, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
Ocugen Inc Info
Ticker SymbolOCGN
Company nameOcugen Inc
IPO dateDec 03, 2014
CEOMusunuri (Shankar)
Number of employees95
Security typeOrdinary Share
Fiscal year-endDec 03
Address11 Great Valley Parkway
CityMALVERN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code19355
Phone14843284701
Websitehttps://ocugen.com/
Ticker SymbolOCGN
IPO dateDec 03, 2014
CEOMusunuri (Shankar)
Company Executives of Ocugen Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Junge Zhang, Ph.D.
Mr. Junge Zhang, Ph.D.
Independent Director
Independent Director
1.17M
+0.01%
Dr. Arun Upadhyay, Ph.D.
Dr. Arun Upadhyay, Ph.D.
Chief Scientific Officer, Head of Research and Development
Chief Scientific Officer, Head of Research and Development
214.50K
+250.87%
Ms. Kirsten Castillo
Ms. Kirsten Castillo
Independent Director
Independent Director
75.00K
+50.00%
Mr. Ramesh Ramachandran, CPA
Mr. Ramesh Ramachandran, CPA
Chief Accounting Officer
Chief Accounting Officer
1.80K
--
Ms. Tiffany Hamilton
Ms. Tiffany Hamilton
Head of Communications
Head of Communications
--
--
Dr. Shankar Musunuri, Ph.D.
Dr. Shankar Musunuri, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Huma Qamar, M.D.
Dr. Huma Qamar, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Uday B. Kompella, Ph.D.
Dr. Uday B. Kompella, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Junge Zhang, Ph.D.
Mr. Junge Zhang, Ph.D.
Independent Director
Independent Director
1.17M
+0.01%
Dr. Arun Upadhyay, Ph.D.
Dr. Arun Upadhyay, Ph.D.
Chief Scientific Officer, Head of Research and Development
Chief Scientific Officer, Head of Research and Development
214.50K
+250.87%
Ms. Kirsten Castillo
Ms. Kirsten Castillo
Independent Director
Independent Director
75.00K
+50.00%
Mr. Ramesh Ramachandran, CPA
Mr. Ramesh Ramachandran, CPA
Chief Accounting Officer
Chief Accounting Officer
1.80K
--
Ms. Tiffany Hamilton
Ms. Tiffany Hamilton
Head of Communications
Head of Communications
--
--
Dr. Shankar Musunuri, Ph.D.
Dr. Shankar Musunuri, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2021
FY2020
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
1.37M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Wed, Dec 10
Updated: Wed, Dec 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Janus Henderson Investors
6.40%
The Vanguard Group, Inc.
4.87%
Millennium Management LLC
1.33%
GMT Capital Corp.
1.33%
BlackRock Institutional Trust Company, N.A.
1.23%
Other
84.83%
Shareholders
Shareholders
Proportion
Janus Henderson Investors
6.40%
The Vanguard Group, Inc.
4.87%
Millennium Management LLC
1.33%
GMT Capital Corp.
1.33%
BlackRock Institutional Trust Company, N.A.
1.23%
Other
84.83%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
8.69%
Investment Advisor
7.89%
Hedge Fund
3.97%
Individual Investor
1.13%
Research Firm
0.49%
Corporation
0.37%
Venture Capital
0.15%
Bank and Trust
0.06%
Other
77.26%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
255
51.36M
16.44%
-32.04M
2025Q2
268
78.45M
26.84%
-13.23M
2025Q1
278
81.07M
27.89%
-11.63M
2024Q4
292
76.62M
26.34%
-21.25M
2024Q3
306
84.66M
29.43%
-6.14M
2024Q2
300
72.04M
27.84%
+19.28M
2024Q1
302
36.88M
14.47%
-15.26M
2023Q4
300
30.54M
12.06%
-31.79M
2023Q3
314
37.28M
14.69%
-34.75M
2023Q2
332
53.23M
20.91%
-28.29M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
14.77M
4.73%
-1.91M
-11.45%
Jun 30, 2025
Millennium Management LLC
5.06M
1.62%
+4.98M
+6121.93%
Jun 30, 2025
GMT Capital Corp.
4.15M
1.33%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.18M
1.66%
-13.04M
-71.54%
Jun 30, 2025
Geode Capital Management, L.L.C.
3.49M
1.12%
-3.40M
-49.37%
Jun 30, 2025
Citadel Advisors LLC
602.01K
0.19%
+354.75K
+143.47%
Jun 30, 2025
State Street Investment Management (US)
1.34M
0.43%
-4.59M
-77.43%
Jun 30, 2025
Musunuri (Shankar Ph.D)
1.34M
0.43%
+607.32K
+82.50%
Apr 14, 2025
Zhang (Junge)
1.17M
0.37%
+117.00
+0.01%
Apr 14, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
Invesco NASDAQ Future Gen 200 ETF
0.82%
Pacer WealthShield ETF
0%
iShares Russell 2000 ETF
0%
iShares Micro-Cap ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
View more
Invesco NASDAQ Future Gen 200 ETF
Proportion0.82%
Pacer WealthShield ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Ocugen Inc?
The top five shareholders of Ocugen Inc are:
The Vanguard Group, Inc. holds 14.77M shares, accounting for 4.73% of the total shares.
Millennium Management LLC holds 5.06M shares, accounting for 1.62% of the total shares.
GMT Capital Corp. holds 4.15M shares, accounting for 1.33% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 5.18M shares, accounting for 1.66% of the total shares.
Geode Capital Management, L.L.C. holds 3.49M shares, accounting for 1.12% of the total shares.
The Vanguard Group, Inc. holds 14.77M shares, accounting for 4.73% of the total shares.
Millennium Management LLC holds 5.06M shares, accounting for 1.62% of the total shares.
GMT Capital Corp. holds 4.15M shares, accounting for 1.33% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 5.18M shares, accounting for 1.66% of the total shares.
Geode Capital Management, L.L.C. holds 3.49M shares, accounting for 1.12% of the total shares.
What are the top three shareholder types of Ocugen Inc?
The top three shareholder types of Ocugen Inc are:
Janus Henderson Investors
The Vanguard Group, Inc.
Millennium Management LLC
Janus Henderson Investors
The Vanguard Group, Inc.
Millennium Management LLC
How many institutions hold shares of Ocugen Inc (OCGN)?
As of 2025Q3, 255 institutions hold shares of Ocugen Inc, with a combined market value of approximately 51.36M, accounting for 16.44% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -10.39%.
What is the biggest source of revenue for Ocugen Inc?
In FY2025Q2, the -- business generated the highest revenue for Ocugen Inc, amounting to -- and accounting for --% of total revenue.
